Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

被引：1
|
作者：
Zhu, Jun [1 ]
Song, Yuqin [1 ]
Li, Jianyong [2 ]
Zhou, Keshu [3 ]
Ke, Xiaoyan [4 ]
Cai, Zhen [5 ]
Zhang, Huilai [6 ]
Yao, Tingting [7 ]
Xia, Zhen [7 ]
Wang, Yiqiu [7 ]
Lai, Peiqiong [7 ]
Liu, Xiaofeng [7 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Med Coll, Dept Hematol, Hangzhou, Peoples R China
[6] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[7] AstraZeneca, Shanghai, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157057
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6496 / 6497
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study
    Yusuf, Rushdia
    Jemielita, Thomas
    Marinello, Patricia
    BLOOD, 2021, 138
  • [32] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)
    Younes, Anas
    Salles, Gilles
    Martinelli, Giovanni
    Bociek, R. Gregory
    Barrigon, Dolores Caballero
    Gonzalez Barca, Eva
    Turgut, Mehmet
    Gerecitano, John F.
    Herbst, Fabian
    Williams, Lisa
    Mukherjee, Nabanita
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2015, 126 (23)
  • [33] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ghosh, Nilanjan
    Munoz, Javier
    Morgan, David S.
    Dang, Nam H.
    Knapp, Mark
    Delioukina, Maria
    Kingsley, Edwin C.
    Anh Tran
    Ping, Jerry
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Ruan, Jia
    BLOOD, 2016, 128 (22)
  • [34] Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Bailey, Neil
    Braun, Tori
    Bailey, Megumi
    Tsomo, Tenzin
    Szeto, Jennie
    Kruidenier, Sandra Benitez
    Dunleavy, Vanessa
    Fesler, Joanna
    Funk, Gayle
    Glennie, Sonia
    Hall, Judson
    Parker, Julia
    Egan, Daniel
    Mawad, Raya
    Dean, Carol A.
    Sullivan, Suzan
    Lu, Chia
    Hohmann, Heidi
    Briggs, Jordan
    Patel, Krish
    BLOOD, 2022, 140 : 3765 - 3766
  • [35] Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Viardot, Andreas
    Goebeler, Mariele
    Pfreundschuh, Michael
    Adrian, Nicole
    Libicher, Martin
    Degenhard, Evelyn
    Stieglmaier, Julia
    Zhang, Alicia
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2013, 122 (21)
  • [36] Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
    Jerkeman, Mats
    Eskelund, Christian Winther
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Toldbod, Helle
    Pedersen, Lone Bredo
    Niemann, Carsten Utoft
    Dahl, Christina
    Kuitunen, Hanne
    Geisler, Christian H.
    Gronbaek, Kirsten
    Kolstad, Arne
    LANCET HAEMATOLOGY, 2018, 5 (03): : E109 - E116
  • [37] Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial
    Huang, Hui-qiang
    Huang, Yunhong
    Yan, Gao
    Yang, Haiyan
    Zhang, Qingyuan
    Yang, Runxiang
    Zhou, Min
    Li, Yufu
    Li, Yan
    Liu, Lihong
    Zhou, Hui
    Jing, Hongmei
    Peng, Zhigang
    Yu, Ding
    Zhang, Rong Yan
    Xu, Bing
    Zhang, Xiaohong
    Qi, Junyuan
    Ma, Liping
    Chen, Shan
    Xue, Jianfei
    BLOOD, 2019, 134
  • [38] Retreatment with bendamustine in patients with relapsed/refractory indolent B-cell lymphoma and mantle cell lymphoma
    Yamada, Toshiki
    Shibata, Yuhei
    Nakamura, Nobuhiko
    Kitagawa, Jun-ichi
    Kasahara, Senji
    Goto, Hideko
    Fukuno, Kenji
    Hara, Takeshi
    Tsurumi, Hisashi
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] RETREATMENT WITH BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL LYMPHOMA AND MANTLE CELL LYMPHOMA
    Yamada, Toshiki
    Nakamura, Nobuhiko
    Kitagawa, Jun-ichi
    Kanemura, Nobuhiro
    Goto, Naoe
    Kasahara, Senji
    Goto, Hideko
    Fukuno, Kenji
    Hara, Takeshi
    Tsurumi, Hisashi
    ANNALS OF ONCOLOGY, 2014, 25
  • [40] An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors
    Oechsle, Karin
    Honecker, Friedemann
    Kollmannsberger, Christian
    Rick, Oliver
    Gruenwald, Victor
    Mayer, Frank
    Hartmann, Joerg T.
    Bokemeyer, Carsten
    ANTI-CANCER DRUGS, 2007, 18 (03) : 273 - 276
12345